Roumell Asset Management Decreased Its Paratek Pharmaceuticals (PRTK) Position by $3.91 Million as Valuation Rose; Locust Wood Capital Advisers Lowered Its Csx (CSX) Holding by $2.99 Million; Stock Rose

February 20, 2018 - By Vivian Currie

Jim Roumell decreased its stake in Paratek Pharmaceuticals Inc (PRTK) by 60.66% based on its latest 2017Q3 regulatory filing with the SEC. Roumell Asset Management Llc sold 156,349 shares as the company’s stock rose 33.85% with the market. The hedge fund run by Jim Roumell held 101,399 shares of the health care company at the end of 2017Q3, valued at $2.55 million, down from 257,748 at the end of the previous reported quarter. Roumell Asset Management Llc who had been investing in Paratek Pharmaceuticals Inc for a number of months, seems to be less bullish one the $424.48 million market cap company. The stock decreased 2.33% or $0.33 during the last trading session, reaching $13.65. About 249,897 shares traded. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has risen 62.03% since February 20, 2017 and is uptrending. It has outperformed by 45.33% the S&P500.

Stephen J. Errico decreased its stake in Csx Corp (CSX) by 14.91% based on its latest 2017Q3 regulatory filing with the SEC. Locust Wood Capital Advisers Llc sold 55,401 shares as the company’s stock rose 3.79% with the market. The hedge fund run by Stephen J. Errico held 316,095 shares of the railroads company at the end of 2017Q3, valued at $17.15 million, down from 371,496 at the end of the previous reported quarter. Locust Wood Capital Advisers Llc who had been investing in Csx Corp for a number of months, seems to be less bullish one the $48.73B market cap company. The stock decreased 2.10% or $1.18 during the last trading session, reaching $54.92. About 3.68M shares traded. CSX Corporation (NYSE:CSX) has risen 97.18% since February 20, 2017 and is uptrending. It has outperformed by 80.48% the S&P500.




Among 10 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Paratek Pharmaceuticals had 24 analyst reports since July 23, 2015 according to SRatingsIntel. On Saturday, August 22 the stock rating was downgraded by Zacks to “Hold”. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) earned “Outperform” rating by Robert W. Baird on Friday, May 13. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has “Buy” rating given on Thursday, June 15 by Leerink Swann. The firm has “Buy” rating given on Friday, June 17 by H.C. Wainwright. The firm earned “Buy” rating on Thursday, July 23 by Gabelli. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, June 29. As per Monday, July 17, the company rating was maintained by Cantor Fitzgerald. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has “Buy” rating given on Tuesday, July 18 by H.C. Wainwright. Robert W. Baird maintained the shares of PRTK in report on Tuesday, October 24 with “Buy” rating. Wedbush maintained Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) on Tuesday, April 4 with “Outperform” rating.

Roumell Asset Management Llc, which manages about $293.14 million and $42.50M US Long portfolio, upped its stake in Marchex Inc (NASDAQ:MCHX) by 245,220 shares to 1.44 million shares, valued at $4.45 million in 2017Q3, according to the filing. It also increased its holding in Seachange Intl Inc (NASDAQ:SEAC) by 271,870 shares in the quarter, for a total of 1.22 million shares, and has risen its stake in Rosetta Stone Inc (NYSE:RST).

Analysts await Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report earnings on March, 1. They expect $-0.72 EPS, up 37.93% or $0.44 from last year’s $-1.16 per share. After $-0.77 actual EPS reported by Paratek Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -6.49% EPS growth.

Investors sentiment decreased to 1.54 in 2017 Q3. Its down 0.35, from 1.89 in 2017Q2. It fall, as 17 investors sold PRTK shares while 29 reduced holdings. 33 funds opened positions while 38 raised stakes. 20.11 million shares or 4.43% more from 19.26 million shares in 2017Q2 were reported. Panagora Asset Inc stated it has 49,195 shares. Proshare Ltd Liability Co has invested 0% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Vanguard Grp Inc Inc invested 0% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Jpmorgan Chase & Com owns 160,781 shares. Water Island Cap Ltd Liability stated it has 0.11% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Verition Fund Mngmt Ltd Company accumulated 10,473 shares. 18,431 are owned by Aqr Cap Mgmt Ltd Llc. Comml Bank Of Ny Mellon Corporation reported 173,102 shares. Millennium Mgmt Ltd Liability holds 334,353 shares. 10,100 are owned by Laurion Management Lp. Stoneridge Invest Ltd Liability holds 0.05% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) or 11,634 shares. Schwab Charles Inv Mgmt Inc holds 0% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) for 82,164 shares. Glg Prns Lp accumulated 124,418 shares. Ameriprise Fin Incorporated holds 21,131 shares. Citadel Advisors Ltd Com holds 93,677 shares or 0% of its portfolio.

Locust Wood Capital Advisers Llc, which manages about $781.63M and $1.06B US Long portfolio, upped its stake in Suncor Energy Inc New (NYSE:SU) by 136,910 shares to 1.45M shares, valued at $50.63 million in 2017Q3, according to the filing. It also increased its holding in Liberty Media Corp Delaware by 320,696 shares in the quarter, for a total of 1.31M shares, and has risen its stake in Danaher Corp Del (NYSE:DHR).

Investors sentiment decreased to 0.66 in 2017 Q3. Its down 0.17, from 0.83 in 2017Q2. It dived, as 56 investors sold CSX shares while 351 reduced holdings. 65 funds opened positions while 204 raised stakes. 612.12 million shares or 2.65% less from 628.79 million shares in 2017Q2 were reported. Forte Limited Liability Adv holds 0.07% of its portfolio in CSX Corporation (NASDAQ:CSX) for 3,987 shares. Australia-based Westpac Bk has invested 0.08% in CSX Corporation (NASDAQ:CSX). Barry Inv Advsrs Ltd Liability Com reported 4,063 shares. Vantage Inv Advsrs Lc reported 9,802 shares. Mutual Of America Cap Mgmt Lc holds 109,921 shares or 0.1% of its portfolio. Alpha Windward Ltd Liability Corp stated it has 1,195 shares or 0.04% of all its holdings. Lmr Prtnrs Ltd Liability Partnership has invested 0.1% in CSX Corporation (NASDAQ:CSX). Parametric Portfolio Ltd Com invested 0.16% in CSX Corporation (NASDAQ:CSX). Kbc Grp Inc Nv invested in 0.1% or 203,383 shares. Commonwealth Equity Svcs Inc stated it has 0.08% of its portfolio in CSX Corporation (NASDAQ:CSX). Wellington Shields Management Ltd Limited Liability Company stated it has 0.16% in CSX Corporation (NASDAQ:CSX). Cibc World Incorporated accumulated 0.02% or 68,439 shares. California Employees Retirement Systems reported 2.28 million shares. Hudson Valley Invest Advsr Adv stated it has 29,636 shares or 0.42% of all its holdings. Hanseatic Management Ser Inc reported 0.09% in CSX Corporation (NASDAQ:CSX).

Among 31 analysts covering CSX Corporation (NYSE:CSX), 19 have Buy rating, 3 Sell and 9 Hold. Therefore 61% are positive. CSX Corporation had 104 analyst reports since August 13, 2015 according to SRatingsIntel. The company was downgraded on Monday, October 16 by Wells Fargo. The firm has “Market Perform” rating by Oppenheimer given on Thursday, June 16. On Thursday, January 14 the stock rating was maintained by RBC Capital Markets with “Outperform”. On Thursday, October 5 the stock rating was maintained by BMO Capital Markets with “Buy”. On Friday, February 12 the stock rating was downgraded by Avondale to “Market Underperform”. The company was initiated on Tuesday, March 15 by Scotia Capital. The firm has “Outperform” rating given on Friday, April 21 by Raymond James. RBC Capital Markets maintained it with “Buy” rating and $59.0 target in Friday, December 15 report. The rating was initiated by Loop Capital with “Hold” on Thursday, August 4. The firm has “Buy” rating given on Friday, December 1 by UBS.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: